Fosfomycin trometamol vs ciprofloxacin for antibiotic prophylaxis before transrectal ultrasonography-guided prostate biopsy: A meta-analysis of clinical studies

Abstract

(2019) Fosfomycin trometamol vs ciprofloxacin for antibiotic prophylaxis before transrectal ultrasonography-guided prostate biopsy: A meta-analysis of clinical studies,

Comparison of Complication Rates with Antibiotic Prophylaxis with Cefpodoxime Versus Fluoroquinolones After Transrectal Prostate Biopsy

“…To the best of our knowledge, there is no published study addressing only cefpodoxime as antibiotic prophylaxis for transrectal prostate biopsy. However, several investigators have compared different antibiotic regimes as antibiotic prophylaxis for transrectal prostate biopsy since the EMA published their recommendation restricting administration of fluoroquinolones because of severe side effects [23][24][25]. For example, Cai et al [26] investigated whether fosfomycin has sufficient efficacy as antibiotic prophylaxis for transrectal prostate biopsy and reported a symptomatic urinary tract infection rate of 1.6%.…”

Evaluation of in vitro susceptibility of fosfomycin among Enterobacteriaceae isolates from urine cultures: A study from Puducherry

“…[7] Currently, it is recommended for the treatment of uncomplicated UTI in adults and as antibiotic prophylaxis in transurethral diagnostic and surgical procedures. [16] Fosfomycin has emerged as a major breakthrough in the treatment of UTI due to increasing proportion of colistin-resistant K. pneumoniae and Proteae with intrinsic nonsusceptibility to colistin in recent years. [16] Furthermore, it was also found to exert an inhibitory effect on biofilms of MDR uropathogens that essentially plays an important role in the pathogenesis of UTI.…”

European Association of Urology Position Paper on the Prevention of Infectious Complications Following Prostate Biopsy

“…The value of fosfomycin trometamol was confirmed in three independent MAs, each including four to five studies comprising nonrandomized trials as well as studies conducted in countries with high fluoroquinolone resistance [10][11][12]. In contrast, in a recent large Canadian nested case-control study with >9000 patients, fosfomycin trometamol (single dose as well as two doses) was inferior to ciprofloxacin (3 d or single dose), which limits the generalizability of the use of fosfomycin trometamol [13].…”